Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E160.83 EPS (ttm)3.15 Insider Own0.90% Shs Outstand103.28M Perf Week1.99%
Market Cap52.32B Forward P/E37.94 EPS next Y13.35 Insider Trans-14.24% Shs Float76.00M Perf Month5.53%
Income358.70M PEG8.07 EPS next Q2.75 Inst Own73.20% Short Float5.74% Perf Quarter20.44%
Sales3.06B P/S17.08 EPS this Y-19.40% Inst Trans1.31% Short Ratio5.25 Perf Half Y24.79%
Book/sh29.07 P/B17.43 EPS next Y20.28% ROA9.40% Target Price503.74 Perf Year70.14%
Cash/sh7.19 P/C70.50 EPS next 5Y19.93% ROE13.70% 52W Range269.50 - 519.46 Perf YTD23.49%
Dividend- P/FCF238.06 EPS past 5Y41.20% ROI12.50% 52W High-0.78% Beta1.05
Dividend %- Quick Ratio4.10 Sales past 5Y49.40% Gross Margin92.00% 52W Low91.25% ATR12.49
Employees2925 Current Ratio4.30 Sales Q/Q39.00% Oper. Margin30.60% RSI (14)68.02 Volatility2.05% 2.78%
OptionableYes Debt/Eq0.16 EPS Q/Q8.20% Profit Margin11.70% Rel Volume0.78 Prev Close506.63
ShortableYes LT Debt/Eq0.16 EarningsMay 07 BMO Payout0.00% Avg Volume830.00K Price515.42
Recom1.90 SMA206.39% SMA509.66% SMA20025.83% Volume216,588 Change1.73%
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
May-19-15Reiterated Brean Capital Buy $507 → $525
May-15-15Reiterated JP Morgan Neutral $427 → $450
May-08-15Reiterated UBS Neutral $412 → $500
May-08-15Reiterated Canaccord Genuity Buy $460 → $525
May-08-15Reiterated Brean Capital Buy $450 → $507
May-07-15Reiterated ROTH Capital Neutral $461 → $490
May-06-15Reiterated Leerink Partners Outperform $527 → $559
Apr-29-15Reiterated RBC Capital Mkts Outperform $490 → $533
Apr-24-15Reiterated Leerink Partners Outperform $445 → $527
Mar-27-15Reiterated Argus Buy $450 → $500
Mar-20-15Initiated Chardan Capital Markets Buy $560
Feb-19-15Downgrade ROTH Capital Buy → Neutral $461
Feb-17-15Reiterated Argus Buy $430 → $450
Feb-11-15Reiterated UBS Neutral $417 → $412
Feb-11-15Reiterated RBC Capital Mkts Outperform $480 → $490
Feb-02-15Reiterated RBC Capital Mkts Outperform $477 → $480
Nov-20-14Reiterated Brean Capital Buy $390 → $450
Nov-19-14Reiterated ROTH Capital Buy $422 → $461
May-26-15 07:14PM  Amgen Gets 1 Step Closer to Another Blockbuster at Investopedia
03:58PM  Amazon, Apple and Chipotle Too Pricey for Your Portfolio? There's an ETF for That at TheStreet
01:00AM  Fight over hot new cholesterol drugs may be won in milligrams Reuters
May-23-15 09:30AM  The Most Loved Biotechs of Big Hedge Funds at 24/7 Wall St.
08:10AM  What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds at Forbes
May-21-15 04:27PM  3 Top IBD 50 Stocks Hit New All-Time Highs
10:30AM  Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis PR Newswire
May-20-15 07:00PM  Cramer: This is the absolute worst thing in this market
06:12PM  Cramer: Bail out now on this group at CNBC
11:07AM  Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying at TheStreet
09:34AM  Move Over Chip Stocks: Here Are 5 Top Biotechs at Investor's Business Daily
09:29AM  10 S&P 500 Companies to Have the Most Revenue Growth in 2015 at TheStreet
09:23AM  Cramer's Mad Dash: Regeneron goes higher
May-19-15 07:00PM  Cramer: This went from $5 to $500 and isn't done
04:51PM  Healthcare Winners and Losers: May 19, 2015
04:40PM  Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog
12:38PM  Regeneron Shares Seen Reaching $525 at Barrons.com
12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
May-18-15 12:30PM  Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference PR Newswire
11:33AM  Regeneron: Why It's Heading to $550 at Barrons.com
08:03AM  Is the Stock Market Due for a Correction?
07:39AM  How to play weak Q2 earnings season: Analysts at CNBC
May-15-15 06:13PM  Health Care Sector Delivers Healthy Q1 Results at Investor's Business Daily
May-13-15 01:04PM  REGENERON PHARMACEUTICALS INC Financials
01:00AM  How DNA sequencing is transforming the hunt for new drugs Reuters
May-11-15 07:16PM  Regeneron, Nike Top Big Cap 20 Stocks Near Buy Points at Investor's Business Daily
May-10-15 08:11PM  10-Q for Regeneron Pharmaceuticals, Inc. at Company Spotlight
May-09-15 08:02AM  Actavis Earnings On Tap After 3 Other IBD 50 Stocks at Investor's Business Daily
May-08-15 06:59PM  Q1 Earnings Drive Industry Group Winners And Losers at Investor's Business Daily
01:31PM  Stocks Surge On Jobs Data; Regeneron Approaches Buy Point at Investor's Business Daily
May-07-15 06:43PM  Medivation, Jazz Q1 Reports Miss; Regeneron Beats at Investor's Business Daily
03:15PM  Regeneron Beats on Q1 Earnings, Eylea 2015 View Upped - Analyst Blog
02:47PM  Stocks Hang On To Solid Gains; Apple Suppliers Ramp Higher at Investor's Business Daily
01:31PM  Regeneron Pharmaceuticals (REGN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
11:29AM  Regeneron expects Eylea sales to grow faster than expected
11:22AM  Regeneron Q1 Earnings Beat As Eylea Research Pays Off at Investor's Business Daily
10:24AM  Regeneron Beats Earnings Forecasts, Gives Back Gains at Barrons.com
10:05AM  Regeneron Earnings Top Estimates as Drug Sales Rise at Bloomberg
08:26AM  Regeneron (REGN) Beats on Q1 Earnings, Updates 2015 View - Tale of the Tape
07:51AM  Early movers: BABA, PCLN, PG, COST, ANN & more at CNBC
07:23AM  Regeneron profit rises as Eylea sales jump
07:16AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Regeneron Reports First Quarter 2015 Financial and Operating Results at noodls
07:07AM  Q1 2015 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:39AM  Regeneron tops Street 1Q forecasts
06:30AM  Regeneron Reports First Quarter 2015 Financial and Operating Results PR Newswire
May-06-15 06:42PM  IBD Market Wrap - 05/06/15
05:41PM  Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks
05:30PM  Regeneron Earnings: Small Growth Expected, Driven By Eylea
04:22PM  Stocks End Lower On Yellen Comment; Biotechs Bounce Back at Investor's Business Daily
02:46PM  What to Watch in the Day Ahead - Thursday, May 7 Reuters
May-05-15 04:20PM  Will Eylea Sales Drive Regeneron (REGN) Q1 Earnings? - Analyst Blog
10:10AM  Stock Market News for May 05, 2015 - Market News
Apr-29-15 10:11AM  Regeneron Announces Upcoming 2015 Investor Conference Presentations at noodls
09:30AM  Regeneron Announces Upcoming 2015 Investor Conference Presentations PR Newswire
Apr-28-15 06:35AM  Mazzone Hospitality creates new division at bizjournals.com
Apr-27-15 05:11PM  More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes at Forbes
Apr-24-15 07:00PM  Cramer's weird Apple Watch moment
11:47AM  Jim Cramer Loves Regeneron, Sees Shares Headed to $500 at TheStreet
09:55AM  Cramer's Stop Trading: Regeneron gets to $500
Apr-23-15 10:44AM  U.S. benchmarks chip away at major resistance at MarketWatch
Apr-22-15 11:43AM  Amgen: But What About the Biosimilars? at Barrons.com
11:10AM  Regeneron Bounces Higher Off Support
Apr-21-15 07:27PM  Amgen tops estimates with 51 percent spike in 1Q profit
Apr-20-15 03:02PM  BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable at Moody's
10:55AM  Cuomo's headed for Cuba, but don't expect a 'Nixon goes to China' moment at bizjournals.com
Apr-19-15 01:54PM  Cuba Mission by Cuomo May Boost Democrats in Swing-State Florida at Bloomberg
Apr-16-15 11:41AM  How Marketing And Media Muddled The Truth About The Heart Drug Vytorin at Forbes
Apr-15-15 05:46PM  Regeneron CEO Joins Cuba Trade Trip With New York Governor Cuomo at Bloomberg
Apr-14-15 12:07PM  Another bad year for stockpickers? Goldman Sachs thinks so
Apr-10-15 10:06AM  Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015 at noodls
09:30AM  Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015 PR Newswire
Apr-08-15 07:00PM  Cramer: How to play the Apple downgrade
10:10AM  Stock Market News for April 08, 2015 - Market News
06:14AM  Jim Cramer -- If You're Not in Biotech for the Long Haul, Hit the Road at TheStreet
Apr-07-15 01:30PM  Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine at noodls
10:41AM  FedEx gains on TNT deal; GM slides as Canada unwinds stake at MarketWatch
Apr-03-15 08:30AM  Don't Miss Your Chance To Buy This High-Ranking Biotech On Sale
Apr-02-15 05:30PM  Biotech run near an end?
Apr-01-15 04:18PM  Economic Indicators Move Equities and Bonds
03:44PM  Esperion Up As UBS Touts Cholesterol Drug at Investor's Business Daily
10:29AM  Stocks Tumble In Heavy Trade; Twitter And Sears Holdings Gain at Investor's Business Daily
Mar-30-15 06:55PM  Cramer: The best places for you to put new money at CNBC
03:50PM  Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog
10:25AM  Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List at Barrons.com
Mar-27-15 07:23PM  Cramer Remix: A bottom in biotech? Hardly at CNBC
06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
04:20PM  Stocks Finish Lower for the Week as Fed Talk Spooks Investors at TheStreet
12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
Mar-26-15 04:14PM  Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog
02:47PM  Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call? at Forbes
02:12PM  Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks at Forbes
10:21AM  Biotech Crash -- How Long Will It Last? at Forbes
10:10AM  Stock Market News for March 26, 2015 - Market News
Mar-25-15 11:57PM  Dow tumbles 292 points as economy shows cracks at CNNMoney.com
08:13PM  Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot at TheStreet
06:00PM  Cramer: Nasdaq's griddle too hot
03:11PM  In A Genetic Portrait Of A Nation, A Map Of The Future at Forbes
02:46PM  Biotechs On Track For Worst Week In A Year at Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM